Dr Charlie Massie
Websites
- CRUK Cambridge Centre: http://crukcambridgecentre.org.uk/users/charliemassie
Graduate Students
Dr Charlie Massie is pleased to consider applications from prospective graduate students.
2018 PhD opportunities:
1. CRUK Cancer Centre Clinical Research Fellowship Programme:
- Project: Developing non-invasive point-of-care tests for prostate cancer for earlier detection of aggressive disease
- How to apply: https://crukcambridgecentre.org.uk/education-and-training/ccc-clinical-research-fellowships-2018
2. CRUK Cambridge Centre MRes/PhD Programme:
- Project: Mapping the origins of tumour development using single-cell technology
- How to apply: https://crukcambridgecentre.org.uk/studentships
3. MRC Doctoral Training Programme:
- Project: Project: Developing a pathway for precision medicine in early stage prostate cancer to reduce radical treatments and improve patient outcomes
- How to apply: https://mrcdtp.medschl.cam.ac.uk/prospective-students/how-to-apply/
Research Interests
We integrate data from cancer genomics, epigenetics, bioinformatics and circulating tumour DNA analysis. Working together with collaborators to provide insights into early disease biology and to build clinically useful tests. At the moment our main focus is on risk stratification and precision medicine in early stage prostate cancer using non-invasive biomarkers and high-sensitivity genomics approaches.
Publications
Pubmed journal articles - pubmed
Key publications
Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, PaceyS, Baird R, Rosenfeld N. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017 Apr;17(4):223-238.
Massie CE, Mills IG, Lynch AG. The importance of DNA methylation in prostate cancer development. JSBMB 2016 pii:S0960-0760(16)30105-4.
Cooper CS, et al; ICGC Prostate Group. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet. 2015;47(4):367-72.
Massie CE, et al; UK Prostate ICGC Group. HES5 silencing is an early and recurrent change in prostate tumourigenesis. ERC 2015;22(2):131-44.
Pertega-Gomes N, ..., Massie CE. Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and
cellular phenotypes in prostate cancer. Oncotarget. 2015;6(25):21675-84.
Asim M, Massie CE, et al. Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. JNCI 2015;108(5).
Chen E, Ahn JS, Massie CE, et al. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. PNAS 2014;111(42):15190-5.
Nangalia J, Massie CE, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. NEJM 2013;369(25):2391-405
Sharma NL, Massie CE, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell. 2013;23(1):35-47
Massie CE, et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30(13):2719-33.